Literature DB >> 26512300

Large eccrine angiomatous hamartoma: a novel clinical presentation of disease.

Uffe Nygaard1, Søren Dalager2, Eva Spaun2, Lene Hedelund1.   

Abstract

BACKGROUND: Eccrine angiomatous hamartoma is a rare benign cutaneous malformation with a diverse clinical appearance, therefore likely to be misdiagnosed and underreported. MAIN OBSERVATIONS: A 44-year-old man presented with a congenital erythematous hyperhidrotic plaque on the left upper back measuring 18 x 25 cm. No pain or tenderness nor hypertrichosis were observed. Histopathology was consistent with the mucinous variant of eccrine angiomatous hamartoma. Intralesional injection of botulinum toxin type A greatly reduced localized sweating, improving patient quality of life.
CONCLUSIONS: This article describes a novel clinical presentation of eccrine angiomatous hamartoma: large, erythematous, and slightly indurated plaque localized on the upper back. It emphasizes the role of histopathology in the diagnostic process and botulinum toxin as a viable treatment option.

Entities:  

Keywords:  botulinum toxin; eccrine angiomatous hamartoma; eccrine naevus

Year:  2015        PMID: 26512300      PMCID: PMC4619160          DOI: 10.3315/jdcr.2015.1211

Source DB:  PubMed          Journal:  J Dermatol Case Rep        ISSN: 1898-7249


  14 in total

Review 1.  Multiple and familial eccrine angiomatous hamartoma.

Authors:  Mónica García-Arpa; María Rodríguez-Vázquez; Pilar Cortina-de la Calle; Guillermo Romero-Aguilera; Rafael López-Pérez
Journal:  Acta Derm Venereol       Date:  2005       Impact factor: 4.437

2.  Eccrine angiomatous hamartoma: a retrospective study of 15 cases.

Authors:  Yi-Ting Lin; Chien-Ming Chen; Chih-Hsun Yang; Yea-Huey Chuang
Journal:  Chang Gung Med J       Date:  2012 Mar-Apr

3.  Successful treatment of eccrine angiomatous hamartoma with botulinum toxin.

Authors:  Didac Barco; Eulàlia Baselga; Marta Alegre; Romà Curell; Agustín Alomar
Journal:  Arch Dermatol       Date:  2009-03

Review 4.  Botulinum toxin for axillary hyperhidrosis.

Authors:  Ada Regina Trindade de Almeida; Suelen Montagner
Journal:  Dermatol Clin       Date:  2014-07-15       Impact factor: 3.478

5.  Eccrine Angiomatous Hamartoma: A Clinicopathological Study of 26 Cases.

Authors:  Tutyana Sanusi; Yanqiu Li; Lan Sun; Chunsen Wang; Youwen Zhou; Changzheng Huang
Journal:  Dermatology       Date:  2015-04-14       Impact factor: 5.366

Review 6.  Congenital eccrine angiomatous hamartoma.

Authors:  O Sanmartin; R Botella; V Alegre; A Martinez; A Aliaga
Journal:  Am J Dermatopathol       Date:  1992-04       Impact factor: 1.533

7.  Late-onset eccrine angiomatous hamartoma: clinical, histological and imaging findings.

Authors:  R H Laeng; J Heilbrunner; P H Itin
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

Review 8.  Eccrine angiomatous hamartoma: a case report and review of the literature.

Authors:  Paul T Martinelli; Jaime A Tschen
Journal:  Cutis       Date:  2003-06

Review 9.  Eccrine angiomatous hamartoma (nevus): immunohistochemical findings and review of the literature.

Authors:  R L Sulica; G F Kao; V I Sulica; N S Penneys
Journal:  J Cutan Pathol       Date:  1994-02       Impact factor: 1.587

Review 10.  Eccrine angiomatous hamartoma.

Authors:  Michelle T Pelle; Howard B Pride; William B Tyler
Journal:  J Am Acad Dermatol       Date:  2002-09       Impact factor: 11.527

View more
  3 in total

Review 1.  Botulinum Toxin Off-Label Use in Dermatology: A Review.

Authors:  Anna Campanati; Emanuela Martina; Katia Giuliodori; Veronica Consales; Ivan Bobyr; Annamaria Offidani
Journal:  Skin Appendage Disord       Date:  2017-02-01

2.  Eccrine Angiomatous Hamartoma With Arteriovenous Malformation: A Rare Entity Re-Explored.

Authors:  Rana S Al-Zaidi; Ghazwa Alotaibi; Mohammed Aljuaid
Journal:  Cureus       Date:  2022-03-30

3.  Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.

Authors:  Emanuela Martina; Federico Diotallevi; Giulia Radi; Anna Campanati; Annamaria Offidani
Journal:  Toxins (Basel)       Date:  2021-02-05       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.